Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2014
09/04/2014WO2014134427A1 Controlling the bioavailability of active ingredients in topical formulations
09/04/2014WO2014134426A1 USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS
09/04/2014WO2014134419A1 Use of ikach blockers for the treatment of cardiac diseases
09/04/2014WO2014134413A2 Cyrrhetinic alkyl esters and protected derivatives thereof
09/04/2014WO2014134394A1 Topical formulations of corticosteroids with enhanced bioavailability
09/04/2014WO2014134391A1 Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
09/04/2014WO2014134388A1 Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
09/04/2014WO2014134380A1 Administration of gamma hydroxybutyrate with monocarboxylate transporters
09/04/2014WO2014134379A1 Method for detection of adenosine and metabolites thereof
09/04/2014WO2014134355A1 Drug combinations
09/04/2014WO2014134349A1 Methods of modulating dlk stability
09/04/2014WO2014134341A1 Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
09/04/2014WO2014134313A1 Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof
09/04/2014WO2014134308A1 Substituted 7-oxo-pyrido [2, 3-d] pyrimidines and their use for the treatment of egfr / erbb2 related disorders
09/04/2014WO2014134306A1 Heterocyclic inhibitors of the sodium channel
09/04/2014WO2014134287A1 Improving cognitive function
09/04/2014WO2014134281A1 Biosynthesis of cannabinoids
09/04/2014WO2014134267A1 Carbazole compounds useful as bromodomain inhibitors
09/04/2014WO2014134251A1 Pharmaceutical compositions
09/04/2014WO2014134240A1 Treatment of cancer with tor kinase inhibitors
09/04/2014WO2014134232A1 Carbazole compounds useful as bromodomain inhibitors
09/04/2014WO2014134202A1 Cancer therapy
09/04/2014WO2014134201A1 A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
09/04/2014WO2014134184A1 Methods of treating ototoxicity
09/04/2014WO2014134169A1 Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
09/04/2014WO2014134132A1 Milk-derived microvesicle compositions and related methods
09/04/2014WO2014134127A1 Cannabinergic nitrate esters and related analogs
09/04/2014WO2014134101A1 Selamectin for treatment of sea lice infestations
09/04/2014WO2014134053A1 Ascorbate esters of omega-3 fatty acids
09/04/2014WO2014134049A1 Delayed release film coatings containing calcium silicate and substrates coated therewith
09/04/2014WO2014133811A2 Compounds from invasive salvinias and methods of using the same
09/04/2014WO2014133361A1 Tricyclic compound and use thereof
09/04/2014WO2014133351A1 Composition for gene delivery comprising chitosan and liquid crystal formation material
09/04/2014WO2014133344A1 Transdermal absorption accelerator and uses thereof
09/04/2014WO2014133197A1 Flagellar and needle complex (injectosome) loop as anti bacterial drug target
09/04/2014WO2014133196A1 Suspension for oral administration comprising amorphous tolvaptan
09/04/2014WO2014132671A1 Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
09/04/2014WO2014132273A1 Substituted sugar derived 1, 2, 3-triazole compounds and their dimers and a process for the preparation thereof
09/04/2014WO2014132267A1 1-substituted, 4-(substituted phenoxymethyl)-1,2,3-triazole compounds with antifungal properties and methods for preparation thereof
09/04/2014WO2014132227A1 Transdermal formulations
09/04/2014WO2014132226A1 Stable dispersible formulation of arterolane maleate and piperaquine and process of preparation thereof
09/04/2014WO2014132220A1 Solid forms of bicyclic heterocyclic derivatives as pdgf receptor mediators
09/04/2014WO2014132218A1 Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters
09/04/2014WO2014132215A1 Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters
09/04/2014WO2014132213A1 Compounds, processes for extracting them from kelp, compositions containing said compounds and use of said compositions
09/04/2014WO2014132205A1 Formulation comprising benzothiazolone compound
09/04/2014WO2014132163A1 Enhanced stability of novel liquid compositions
09/04/2014WO2014132134A1 A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
09/04/2014WO2014132100A1 Mobilizing agents and uses therefor
09/04/2014WO2014132083A2 Hydrogen sulphide compounds
09/04/2014WO2014132060A1 Skincare compositions
09/04/2014WO2014132052A2 Compound and method for the treatment and diagnosis of neurodegenerative conditions
09/04/2014WO2014131892A1 Cell-penetrating oligonucleotides
09/04/2014WO2014131855A1 Novel compounds as dual inhibitors of phosphodiesterases and histone deacetylases
09/04/2014WO2014131852A1 Combinations comprising maba compounds and corticosteroids
09/04/2014WO2014131851A1 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES
09/04/2014WO2014131847A1 Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
09/04/2014WO2014131825A1 Pharmaceutical formulations comprising quetiapine and escitalopram
09/04/2014WO2014131777A1 Inhibitors of histone demethylases
09/04/2014WO2014131376A1 Electrospun nanofibers comprising pharmaceutically active agents
09/04/2014WO2014131315A1 Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
09/04/2014WO2014131113A1 Thermostable nuclease
09/04/2014WO2014110163A3 Melk regulation for the treatment of breast cancer
09/04/2014WO2014109725A3 Use of glycyl glutamine against depression
09/04/2014WO2014108571A3 Cancer drug and uses
09/04/2014WO2014080285A3 Pharmaceutical compositions having improved storage stability
09/04/2014WO2013179264A4 Compounds modulating astrocytic release of substances through connexins and pannexins and treatment of psychiatric disorders
09/04/2014WO2013134085A8 Inhibitors of beta-secretase
09/04/2014WO2013123588A9 Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
09/04/2014WO2013106535A9 Irak inhibitors and uses thereof
09/04/2014WO2013090457A3 In vivo delivery of oligonucleotides
09/04/2014WO2009134574A3 Disubstituted phthalazine hedgehog pathway antagonists
09/04/2014US20140249490 Methods for Prevention and/or Treatment of Capsular Contracture
09/04/2014US20140249347 Use of pyridone derivatives in the prevention or treatment of tissue or organ toxicity induced by cytotoxic agents and radiation
09/04/2014US20140249317 Compositions for oral administration of zoledronic acid or related compounds for treating disease
09/04/2014US20140249235 Pharmaceutical Compositions With Enhanced Performance and Improved Processability
09/04/2014US20140249234 Compositions and Methods for Restoring the Stratum Corneum and Treating Dermatological Diseases
09/04/2014US20140249233 Method for enhancing folding and transport of misfolded glucocerebrosidase
09/04/2014US20140249232 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
09/04/2014US20140249231 Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
09/04/2014US20140249230 Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
09/04/2014US20140249229 Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
09/04/2014US20140249228 Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
09/04/2014US20140249227 Lipid composition for the prevention or treatment of skin problems
09/04/2014US20140249226 Methods of administering compositions comprising docosapentaenoic acid
09/04/2014US20140249225 Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
09/04/2014US20140249224 Methods for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child
09/04/2014US20140249223 Methods for improving brain development and cognitive function using beta-hydroxy-beta methylbutyrate
09/04/2014US20140249222 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
09/04/2014US20140249221 Tri-Salt Form of Metformin
09/04/2014US20140249220 Compositions and methods for reducing a fatty acid desaturation index in a subject in need thereof
09/04/2014US20140249219 Anti-obesity potential of Calebin A
09/04/2014US20140249218 Administration of ingenol mebutate
09/04/2014US20140249217 Enhancer of survival of transplanted organ
09/04/2014US20140249214 Co-administration of warfarin and ethyl eicosapentaenoate
09/04/2014US20140249203 Nanoparticles stabilized with nitrophenylboronic acid compositions
09/04/2014US20140249202 Targeted nanoparticles
09/04/2014US20140249200 Co-administration of atorvastatin and ethyl eicosapentaenoic acid or a derivative thereof
09/04/2014US20140249199 Tak1 kinase inhibitors, compositions, and used related thereto
09/04/2014US20140249198 Melatonin and its use in preventing postoperative complications
1 ... 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 ... 7860